#Genomics on social media is mainstream. Kinda boring. Don't follow the herd

This is how old the MiSeq is. (Its SEO is outperforming the i100)

Do you want to know the truth? . Or do you want videos of my lab with moving Pipette heads and a stream of sequencing data that I’ll illustrate as Sanger traces?.

For large co’s that try to integrate products that they acquire, how synergistic is this really?. It is so hard to do due diligence esp when spreading into new business areas. Some established integrators succeed but many companies are poor at this, especially younger ones. 🐄.

Some large co’s give freedom for companies to innovate, but they control their finances. Will they approve investments if performance isn’t great? No.

2- We see and expect more consolidation. The short term winners are the sellers (make some 💰or stop their losses) and the customers (can continue to use products). But what if the long term for the buyer and the technology?.

Many genomics companies face this when growth slows. When you have so few resources to spend due to recent performances, will you risk your best products or ecke out some new bets with sufficient attention and 💰?. Disruptive innovation doesn’t provide short term revenue needed.

1- The innovator’s dilemma is real, the fear of losing premium position on the highest revenue/profitable products, but is often justifiable.

Long, great thread on strategy. Two thorts for genomics for the times we find ourselves in:.

So what can we do about it?. We ways to keep them at their computer.No conferences. No sales meetings. Just plan their day to go to endless reporting and approval meetings. And if they have to meet - no freakin’ alcohol!. Yes, and no customers either!. 🐮.

We can’t let this happen again. Every time execs bond they come up with new ideas that interrupt the last set of ideas they asked us to work on 🛑 . It’s even worse when a customer is involved. Their 1 customer interaction a month trumps routine strategic planning.

Does the department we’re going to ask to help know about this?. Yes, but they don’t report to these execs. So the pressure isn’t on them and they won’t reprioritize. Is the budget secured?. Not yet. They’ll make it happen they said. So I just say “Simon says”? 👮.

So does this mean that my other activities /annual goals get put aside for this?. No, these are stretch goals 💪. Everything is a stretch goal these days. Is this project managed?. Nope. The execs said it would be easy. So we just have to do it 🫡.

This work wasn’t scheduled, budgeted, nor prioritized among existing activities. But this is important the staff said. It comes from the execs!. 💪.

Two execs talked in a bar 🥂 . Work for others get created 🚨 . A tale as old as time . 🧵

Epigenica Raises $2.2M to Support Commercial Growth. Cow-ardly predictions🥁:.Never hear about this company or idea after a few years, or Illumina has to buy a competitor in this space 🐮

As Illumina invests into proteomics, their dream customers are investing elsewhere 🐮.

- it doesn’t correlate well with other methods like Elisa. This is possibly an industry wide issue with affinity approaches even between antibody approaches, but aptamers are the only non-antibody approach… in a world where diagnostic testing is mostly based on Elisa.

- not mix and match. Seems to affect binding rates so may need reoptimozation.- doesn’t work well in situ.- needs specific buffers based on the sample type.- afaik never used well as a therapeutic. And importantly. .

Aptamers bind with high precision, scale, and are easy to remanufacture. But before we start ditching our abcam stock remember they have had these drawbacks in the past.

On a scale of 1-4 (4 = high competence) . How confident are you with confocal microscopy?.